Natera successfully secured a preliminary injunction against NeoGenomics, establishing its likelihood of winning its patent infringement claims regarding its cancer testing products, Signatera and RaDaR.
The district court emphasized the significance of patent rights in the oncology testing industry, asserting that the preliminary injunction will protect Natera's innovations and ensure fair competition among healthcare providers.
NeoGenomics argued that the preliminary injunction would jeopardize ongoing research projects, indicating the potential negative impact of the injunction on clinical research and innovation in oncology testing.
Despite NeoGenomics' concerns, the district court maintained the injunction emphasized that patent protections are crucial for investment in developing new cancer detection technologies.
#patent-infringement #healthcare-research #oncology-testing #legal-proceedings #preliminary-injunction
[
Collection
]
[
|
...
]